100+ Page Summary of London CFS Conference

[Guest guest]

This link :

http://www.investinme.org/Documents/Journals/Journal%20of%20IiME%20Vol%206%20Iss\

ue%201%20Screen.pdf

has a summary of the London CFS Conference.

Some noteworthy points from the article here:

page 20:

Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

(ME/CFS) and Fibromyalgia (FM) with a Staphylococcus Vaccine

Page 100:

our investigations have

shown dysfunction in Natural Killer cell lysis,

Natural Killer Cell Phenotype, Cytotoxic T cell

Cytotoxic Lysis, GZMA lytic protein decreases for

NK and T Cytotoxic cell function, Neuropeptide

receptor dysfunction (VPAC1R and VPAC2R), Foxp3

expression, Cytokine dysregulation (T-Helper 1 and

T-Helper 2 Dysregulation) and microRNA immune

regulation in CFS patients compared to nonfatigued

controls. These collective studies suggest

their application as potential biomarkers for early

identification of ME/CFS patients for clinicians.

sat down with one of the most

respected ME/CFS-clinicians, , and

asked him his thoughts.

- I think it is a crucial step forward, he told me.

And then he went on to say that he had seen

effects of Rituximab himself. Several of his ME/CFS

patients had developed lymphoma and therefore

got treated with Rituximab, one of them for

several years.

- And after starting treatment his ME/CFS

symptoms disappeared, said .